2020
Association of cytoreductive nephrectomy and survival in the immune checkpoint inhibitor era.
Miccio J, Ma S, Oladeru O, Yang D, Peters G, Jethwa K, Park H, Hurwitz M, Leapman M, Sprenkle P, Nguyen P, Yu J, Johung K. Association of cytoreductive nephrectomy and survival in the immune checkpoint inhibitor era. Journal Of Clinical Oncology 2020, 38: 748-748. DOI: 10.1200/jco.2020.38.6_suppl.748.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaCytoreductive nephrectomyICI eraImproved overall survivalNational Cancer DatabaseOverall survivalIFN eraFuhrman gradeBenefit of CNEfficacy of ICIsClinical T stageCox regression analysisTreatment facility typeRenal cell carcinomaCARMENA trialInterferon eraMultivariable associateN0 diseaseOS benefitProspective reevaluationMedian ageT stageCell carcinomaCancer DatabasePartial nephrectomy
2016
National sociodemographic disparities in the treatment of high‐risk prostate cancer: Do academic cancer centers perform better than community cancer centers?
Mahal B, Chen Y, Muralidhar V, Mahal A, Choueiri T, Hoffman K, Hu J, Sweeney C, Yu J, Feng F, Kim S, Beard C, Martin N, Trinh Q, Nguyen P. National sociodemographic disparities in the treatment of high‐risk prostate cancer: Do academic cancer centers perform better than community cancer centers? Cancer 2016, 122: 3371-3377. PMID: 27434225, DOI: 10.1002/cncr.30205.Peer-Reviewed Original ResearchMeSH KeywordsAcademic Medical CentersAgedBlack or African AmericanCancer Care FacilitiesCommunity Health ServicesDatabases, FactualDemographyFollow-Up StudiesHealthcare DisparitiesHispanic or LatinoHumansMaleMedically UninsuredNeoplasm GradingNeoplasm StagingPrognosisProstatic NeoplasmsQuality of Health CareRisk FactorsSocioeconomic FactorsUnited StatesWhite PeopleConceptsHigh-risk prostate cancerCommunity cancer centerProstate cancerAcademic cancer centerCancer CenterDefinitive therapyTreatment delayTreatment of high-risk prostate cancerAcademic centersNational Cancer Data BaseMultivariate Cox regression analysisSociodemographic disparitiesHigh-risk cancerCancer treatment patternsMultivariate Cox regressionTiming of therapyCox regression analysisMultivariate logistic analysisTreatment disparitiesCommunity centersExperience treatment delaysUninsured patientsTreatment patternsGray's testCox regression
2010
Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation
Galper S, Yu J, Mauch P, Strasser J, Silver B, LaCasce A, Marcus K, Stevenson M, Chen M, Ng A. Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation. Blood 2010, 117: 412-418. PMID: 20858859, DOI: 10.1182/blood-2010-06-291328.Peer-Reviewed Original ResearchConceptsStandardized incidence ratioClinically significant cardiac diseaseSignificant cardiac diseaseMediastinal irradiationAbsolute excess riskCardiac eventsCardiac proceduresIncidence rate of cardiac eventsCardiac diseaseRate of cardiac eventsExcess riskSurvivors of Hodgkin lymphomaCoronary artery bypass graftingMedian follow-upCox regression analysisArtery bypass graftingCumulative incidence rateAssociated with excess riskImplantable cardioverter defibrillatorHodgkin lymphomaRadiation therapyValve surgeryCardiac surveillanceCardiac complicationsPacemaker placement